Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 252	$ 3,757
Property, plant and improvements
Property and equipment, net		148,125
Other assets
Operating lease right-of-use assets		229,284
Other receivable	279,866	424,110
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	1,170,328	1,065,328
Intangible assets, net	5,062,350	5,380,959
Total assets	6,557,655	7,296,422
Current liabilities
Accounts payable	211,294	181,266
Accounts payable – related parties	8,347
Loans payable	10,113,634	10,121,411
Loans payable – related parties	1,361,618	1,362,600
Convertible notes payable	6,293,650	5,185,412
Convertible notes payable- related parties	2,558,681	2,538,681
Accrued interest	11,917,412	9,585,055
Accrued interest – related parties	1,527,313	1,274,899
Lease liabilities	15,750	44,361
Accrued expenses	609,823	574,723
Total current liabilities	34,617,522	30,868,408
Lease liabilities, less current portion	138,754	184,263
Patent acquisition liability	720,000	720,000
Convertible notes, less current portion	427,360	1,038,913
Convertible notes - related parties, less current portion		20,000
Total liabilities	35,903,636	32,831,584
Shareholders’ deficit
Common stock; unlimited authorized shares; 27,512,363 issued and outstanding and 26,953,363 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively. No par value.
Additional paid-in capital	16,850,360	15,775,010
Accumulated deficit	(46,196,341)	(41,310,172)
Total shareholders’ deficit	(29,345,981)	(25,535,162)
Total liabilities and shareholders’ deficit	$ 6,557,655	$ 7,296,422